Home  /  Resource Library  /  Ixazomib With or Without Rituximab Following Maintenance Autologous Stem Cell Transplant in Mantle Cell Lymphoma: A Single-Center Phase I Trial

Ixazomib With or Without Rituximab Following Maintenance Autologous Stem Cell Transplant in Mantle Cell Lymphoma: A Single-Center Phase I Trial

Results of a study investigating ixazomib combined with Rituximab as maintenance therapy following autologous stem cell transplant for treatment of mantle cell lymphoma.